InflaRx NV (IFRX) Stock Analysis
Verdict: WATCH (do not buy)
A high-beta race against time where promising C5a clinical data must beat a terminal cash runway currently estimated at under 6 months.
Investment score: 42/100
Analysis as of
Is InflaRx NV stock worth reviewing? The TradeMates thesis
InflaRx is a speculative biotech play with a critically short cash runway (approx. 6 months based on 2025 burn). Despite 11/14 analysts maintaining Buy/Strong Buy ratings and a $9 price target, the fundamental reality of -35,000% operating margins and impending dilution makes the risk-reward unfavorable at $1.82.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 35/100 (weight 15%)
- Technical Momentum: 55/100 (weight 15%)
- Earnings Quality: 50/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
InflaRx NV opportunities and risks
What speaks for IFRX
- Phase III PG & Vasculitis Expansion
What speaks against IFRX
- Imminent Liquidity Crunch and Dilution
Peers and competitors
- NNNN
- IMTX
- FYB.DE
- HPHA.DE
- 7V0.DE
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| IFRX | n/a | 3911.5x | n/a | -24646.3% | -146303.9% | -25.2% |
| NNNN | 96.9x | 71.4x | 106.3x | 87.1% | 73.7% | 0.2% |
| IMTX | n/a | 29.9x | n/a | 100.0% | -574.9% | -16.9% |
| Peer median | 45.8x | 50.7x | 51.1x | 93.5% | -250.6% | -8.3% |
Frequently asked questions about InflaRx NV (IFRX)
Is IFRX stock a good investment?
The TradeMates model rates InflaRx NV as WATCH (do not buy) with an investment score of 42/100. InflaRx is a speculative biotech play with a critically short cash runway (approx. 6 months based on 2025 burn). Despite 11/14 analysts maintaining Buy/Strong Buy ratings and a $9 price target, the fundamental reality of -35,000% operating margins and impending dilution makes the risk-reward unfavorable at $1.82. This is algorithmic model output, not personal investment advice.
Is IFRX stock a buy?
The TradeMates model verdict for IFRX is WATCH (do not buy) with an investment score of 42/100. Treat this as a model signal to review, not a personal buy recommendation.